AIDS Deals Heat Up--In Both Private and Public Sectors
Executive Summary
Abbott Laboratories' Norvir (ritonavir) set a record early in March: the FDA reviewed and approved the protease inhibitor for use alone or in combination therapy as a treatment for late-stage AIDS just 72 days after filing.
You may also be interested in...
Clinical Update: AIDS Research Marches On
A short discussion of the state of HIV/AIDS research, including drug and vaccine development, reversing AIDS' destructive process, and new studies in this area.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.